PURPOSE: We evaluate the feasibility and efficacy of S-1 in combination with cisplatin (CDDP) for patients with colorectal cancer. METHODS: A total of 52 patients with advanced or recurrent colorectal cancer were included. S-1 was given orally twice daily for 21 days and CDDP 30 mg/m(2) on day 1 and 8, followed by a 2-week period of no treatment. RESULTS: Tumor responses among patients included 18 PR, 12 SD, and 16 PD (n = 46). The overall response rate was 36.4% (18/46). The response rate of the patients with prior chemotherapy was 22.2% (4/18) and 50.0% (12/24) among the patients who had no prior therapy. The median survival periods were 555 days and the median progression free survival periods were 183 days, respectively. S-1 in combination with CDDP shows promising activity with acceptable toxicities against colorectal cancer. CONCLUSIONS: A combination of S-1 and CDDP could be a standard therapy for treating colorectal carcinoma.
PURPOSE: We evaluate the feasibility and efficacy of S-1 in combination with cisplatin (CDDP) for patients with colorectal cancer. METHODS: A total of 52 patients with advanced or recurrent colorectal cancer were included. S-1 was given orally twice daily for 21 days and CDDP 30 mg/m(2) on day 1 and 8, followed by a 2-week period of no treatment. RESULTS: Tumor responses among patients included 18 PR, 12 SD, and 16 PD (n = 46). The overall response rate was 36.4% (18/46). The response rate of the patients with prior chemotherapy was 22.2% (4/18) and 50.0% (12/24) among the patients who had no prior therapy. The median survival periods were 555 days and the median progression free survival periods were 183 days, respectively. S-1 in combination with CDDP shows promising activity with acceptable toxicities against colorectal cancer. CONCLUSIONS: A combination of S-1 and CDDP could be a standard therapy for treating colorectal carcinoma.
Authors: F Maindrault-Goebel; C Louvet; T André; E Carola; J P Lotz; J L Molitor; M L Garcia; V Gilles-Amar; V Izrael; M Krulik; A de Gramont Journal: Eur J Cancer Date: 1999-09 Impact factor: 9.162
Authors: A de Gramont; J F Bosset; C Milan; P Rougier; O Bouché; P L Etienne; F Morvan; C Louvet; T Guillot; E François; L Bedenne Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544
Authors: M M Borner; P Schoffski; R de Wit; F Caponigro; G Comella; A Sulkes; G Greim; G J Peters; K van der Born; J Wanders; R F de Boer; C Martin; P Fumoleau Journal: Eur J Cancer Date: 2002-02 Impact factor: 9.162
Authors: T Taguchi; Y Inuyama; R Kanamaru; K Hasegawa; S Akazawa; H Niitani; H Furue; M Kurihara; K Ota; S Suga; Y Ariyoshi; S Takai; T Shimoyama; T Toge; S Takashima; K Sugimachi; Y Hara; H Fujita; K Kimura; T Saito; S Tsukagoshi; I Nakao Journal: Gan To Kagaku Ryoho Date: 1997-12